Article Figures & Data
Figures
- FIGURE 1.
Flowchart of Bad Berka dose protocol. ROI = region of interest; VOI = volume of interest.
- FIGURE 2.
PRLT posttherapy scans and SPECT maximum-intensity-projection (MIP) image. (A) Scans after 177Lu-PSMA I&T. (B) Scans after 177Lu-PSMA-617. p.i. = after injection.
- FIGURE 3.
Biodistribution and dosimetry results for normal organs in patients treated with different PSMA ligands. (A) Kinetics: median uptakes in percentage administered activity. (B) Median effective half-life in hours. (C) Median residence time in hours. (D) Mean absorbed doses in Gy/GBq.
- FIGURE 4.
Kinetics of metastases and comparative results from 96 metastases (bone, lymph node, liver, lung, and other) of patients treated with 177Lu-PSMA I&T and from 179 tumor lesions (bone, lymph node, liver, lung, and other) of patients treated with 177Lu-PSMA-617. (A) Median kinetics of all types of metastases. (B) Median kinetics of bone metastases. (C) Median kinetics of lymph node metastases. After administration of therapeutic activity, higher initial uptakes and faster washout for 177Lu-PSMA I&T were observed in bone and lymph node lesions. In contrast, curves of 177Lu-PSMA-617 showed initial increase until 3 h after injection. %IA = percentage injected activity.
- FIGURE 5.
Comparative dosimetry results of metastases. (A) Median effective half-life. (B) Median residence time. (C) Mean absorbed dose.
- FIGURE 6.
Comparison of laboratory parameters (hemoglobin, leukocyte, platelet, and serum creatinine) before therapy, after 2 cycles, and after 2–6 cycles with long-term follow up (FU) (observation period, 3.2–48.5 mo; mean ± SD, 17.4 ± 11.9 mo; median, 13.2 mo) for 177Lu-PSMA I&T and 177Lu-PSMA-617 PRLT.
Tables
Characteristic All patients 177Lu-PSMA I&T group 177Lu-PSMA-617 group Number of patients 138 51 87 Age (y) 70 ± 9 (46–90) 71 ± 9 (46–87) 69 ± 9 (50–90) ISUP grading Group 1 7 (5.1%) 2 (3.9%) 5 (5.7%) Group 2 20 (14.5%) 3 (5.9%) 17 (19.5%) Group 3 21 (15.2%) 10 (19.6%) 11 (12.6%) Group 4 26 (18.8%) 6 (11.8%) 20 (23.0%) Group 5 39 (28.3%) 18 (35.3%) 21 (24.1%) NA 25 (18.1%) 12 (23.5%) 13 (14.9%) PSA level (ng/mL) 216.5 ± 538.7 90.6 ± 158.7 283.3 ± 648.2 Metastases Lymph nodes 109 (79.0%) 38 (74.5%) 71 (81.6%) Bone 108 (78.2%) 39 (76.5%) 69 (79.3%) Bone marrow 11 (8.0%) 2 (3.9%) 9 (10.3%) Lung 15 (10.9%) 6 (11.8%) 9 (10.3%) Liver 12 (8.7%) 4 (7.8%) 8 (9.2%) Other 36 (26.1%) 10 (19.6%) 26 (29.9%) Injected activity (GBq) 6.4 ± 1.0 (3.4–9.0) 6.1 ± 1.0 (3.4–7.6) 6.5 ± 1.1 (3.5–9.0) ISUP = International Society of Urological Pathology; NA = not available; PSA = prostate-specific antigen.
Qualitative data are number and percentage; continuous data are mean and range.
- TABLE 2.
Hematotoxicity and Nephrotoxicity after 177Lu-PSMA I&T PRLT According to Common Terminology Criteria for Adverse Events, version 5.0 (n = 35)
Numbers of patients with… Anemia Leukocytopenia Thrombocytopenia Nephrotoxicity Grade Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU CTC-1 21 30 24 5 3 6 1 2 8 5 5 7 CTC-2 1 2 8 1 1 2 0 1 1 0 0 0 CTC-3 0 0 1 0 0 1 0 0 0 0 0 0 CTC-4 0 0 0 0 0 0 0 0 0 0 0 0 CTC-5 NA 0 0 NA 0 0 NA 0 0 NA 0 0 FU = follow-up; CTC = Common Terminology Criteria grade; NA = not applicable before therapy (grade 5 represents death).
- TABLE 3.
Hematotoxicity and Nephrotoxicity After 177Lu-PSMA-617 PRLT According to Common Terminology Criteria for Adverse Events, version 5.0 (n = 66)
Numbers of patients with… Anemia Leukocytopenia Thrombocytopenia Nephrotoxicity Grade Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU Pretherapy After 2 cycles Long- term FU CTC-1 44 45 46 8 12 12 7 12 15 11 12 12 CTC-2 7 14 14 1 3 5 1 2 4 2 1 2 CTC-3 0 0 0 0 1 1 0 0 4 0 0 0 CTC-4 0 0 0 0 0 0 0 0 0 0 0 0 CTC-5 NA 0 0 NA 0 0 NA 0 0 NA 0 0 FU = follow-up; CTC = Common Terminology Criteria grade; NA = not applicable before therapy (grade 5 represents death).
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
- Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists
- Localized In Vivo Prodrug Activation Using Radionuclides
- Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
- Feasibility of 177Lu-PSMA Administration as Outpatient Procedure for Prostate Cancer
- Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer
- Localized in vivo prodrug activation using radionuclides
- Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis
- Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T
- Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
- The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease
- Unraveling the Impact of 177Lu-PSMA Radioligand Therapy on Renal Impairment: Distinguishing Causation from Correlation
- An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
- Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
- Toward Single-Time-Point Image-Based Dosimetry of 177Lu-PSMA-617 Therapy
- A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake